The effects of grapefruit juice on sertraline metabolism: An in vitro and in vivo study

Bailey, 1994, Grapefruit juice and drugs—how signifi-cant is the interaction?, Clin Pharma-cokinet, 26, 91, 10.2165/00003088-199426020-00002 Benton, 1996, Grapefruit juice alters terfenadine phar-macokinetics, resulting in prolongation of repolarization on the electrocardiogram, Clin Pharmacol Ther, 59, 383, 10.1016/S0009-9236(96)90105-8 Ducharme, 1995, Disposition of intravenous and oral cyclosporine after administration with grapefruit juice, Clin Pharmacol Ther, 57, 485, 10.1016/0009-9236(95)90032-2 Lundahl, 1997, Effects of grapefruit juice ingestion—pharmacokinetics and haemody-namics of intravenously and orally administered felodipine in healthy men, Eur J Clin Pharmacol, 52, 139, 10.1007/s002280050263 Bailey, 1995, Grapefruit juice-felodipine interaction: Reproducibility and characterization with the extended release drug formulation, Br J Clin Pharmacol, 40, 135 Lown, 1997, Grapefruit juice increases felodipine oral availability in humans by decreasing in-testinal CYP3A protein expression, J Clin Invest, 99, 2545, 10.1172/JCI119439 Josefsson, 1996, Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers, Eur J Clin Pharmacol, 51, 189, 10.1007/s002280050183 Weber, 1996, Can grapefruit influence ethinylestradiol bioavailability?, Contraception, 53, 41, 10.1016/0010-7824(95)00252-9 Kupferschmidt, 1995, Interaction between grapefruit juice and midazolam in humans, Clin Pharmacol Ther, 58, 20, 10.1016/0009-9236(95)90068-3 Hukkinen, 1995, Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice, Clin Pharmacol Ther, 58, 127, 10.1016/0009-9236(95)90188-4 He, 1998, Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice, Chem Res Toxicol, 11, 252, 10.1021/tx970192k Schmiedlin-Ren, 1997, Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents. Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocou-marins, Drug Metab Dispos, 25, 1128 Murdock, 1992, Sertraline: A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive-compulsive disorder, Drugs, 44, 604, 10.2165/00003495-199244040-00007 Preskorn, 1997, Clinically relevant pharmacology of selective serotonin reuptake in-hibitors—an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism, Clin Pharmacokinet, 32, 1, 10.2165/00003088-199700321-00003 Fabre, 1995, Sertraline safety and efficacy in major depression: A double-blind fixed-dose com-parison with placebo, Biol Psychiatry, 38, 592, 10.1016/0006-3223(95)00178-8 Pohl, 1998, Sertraline in the treatment of panic disorder: A double-blind multicenter trial, Am J Psychiatry, 155, 1189, 10.1176/ajp.155.9.1189 Finley, 1994, Selective serotonin reuptake inhibitors: Pharmacologic profiles and po-tential therapeutic distinctions, Ann Pharmacother, 28, 1359, 10.1177/106002809402801207 Ronfeld, 1997, Pharmacokinetics of sertraline and its N-desmethyl metabolite in elderly and young male and female volunteers, Clin Pharmacokinet, 32, 22, 10.2165/00003088-199700321-00004 Sprouse, 1996, Comparison of the effects of sertraline and its metabolite desmethylsertraline on block-ade of central 5-HT reuptake in vivo, Neu-ropsychopharmacology, 14, 225, 10.1016/0893-133X(95)00112-Q Logan, 1994, Analysis of sertraline (Zoloft) and its major metabolite in postmortem specimens by gas and liquid chromatography, J Anal Toxicol, 18, 139, 10.1093/jat/18.3.139 Edwards, 1997, Relationship between 6′,7′-dihydroxybergamottin concentration in grapefruit juice and in vitro inhibition of CYP3A activity, 309 Ketter, 1995, The emerging role of cytochrome P450 3A in psychopharmacology, J Clin Psychopharmacol, 15, 387, 10.1097/00004714-199512000-00002